Patents by Inventor Fayyaz Sutterwala

Fayyaz Sutterwala has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Reversal of proinflammatory response by ligating the macrophage FcgammaRI receptor
    Publication number: 20040062763
    Abstract: Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
    Type: Application
    Filed: September 19, 2003
    Publication date: April 1, 2004
    Applicant: Temple University - Of The Commonwealth System of Higher Education
    Inventors: David M. Mosser, Fayyaz Sutterwala
  • Reversal of proinflammatory response by ligating the macrophage Fc&ggr;RI receptor
    Patent number: 6660266
    Abstract: Ligation of the Fc&ggr; receptor type I (Fc&ggr;RI) on IL-10-producing cells leads to a selective upregulation of IL-10 production, which in turn induces a marked suppression of IL-12 biosynthesis by IL-12-producing cells, particularly macrophages. The ligation of the Fc&ggr;RI receptor thus downmodulates IL-12 production via a mechanism that is dependent on macrophage-derived IL-10. Agents for ligating Fc&ggr;RI comprise, for example, multivalent antibodies which bind the Fc&ggr;RI receptor, immune complexes comprising antibodies which contain the Fc region of IgG, and IgG multimers, preferably IgG dimers and trimers. The ligating agent may be administered to therapeutically inhibit proinflammatory immune responses. In particular, the ligating agent may be administered to treat or prevent endotoxic shock associated with bacterial endotoxemia, and to treating autoimmune disorders.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: December 9, 2003
    Assignee: Temple University - of The Commonwealth System of Higher Education
    Inventors: David M. Mosser, Fayyaz Sutterwala